IL-15 is a pro-inflammatory cytokine whose three-dimensional structure is similar to that of IL-2. IL-2 and IL-15 have similar as well as distinct biological functions. An active form of IL-15 that is membrane bound has also been described. Furthermore, IL-15 is known to play a role in autoimmune diseases. We thus investigated the expression of membrane bound IL-15 on monocytes (CD14+ cells) and studied its effect on T cell activation in MS patients. We found that unstimulated CD14+ cells from relapsing remitting MS patients had increased membrane bound IL-15. Those with high surface levels of IL-15 on monocytes were in the early stages of the disease. In addition, we found that T cells of MS patients had enhanced responsiveness to IL-15 and there was increased expression of IL-15 receptor on CD4+ T cells. Thus, IL-15 may be an important cytokine that drives Th1 responses early in the course of the disease and could serve as a target for immunotherapy and as an early marker in the immunologic staging of MS.
Introduction
IL-15 is a 14-kDa pro-inflammatory cytokine whose threedimensional structure is similar to that of IL-2 and some biological functions of these cytokines are similar as well. For binding and signaling, IL-15 uses the γ and β subunits of the IL-2R as well as the specific IL-15Rα chain (Giri et al., 1994; Giri et al., 1995; Grabstein et al., 1994) . IL-15 mRNA has been detected in a variety of tissues and cells but its protein is produced mainly by peripheral blood monocytes, macrophages, dendritic cells, activated astrocytes and microglia (Waldmann and Tagaya, 1999) . Like IL-15, IL-15 receptor (IL-15R) has a wide cellular distribution. It is expressed on T cells, B cells, macrophages, thymic cells, skeletal, lung and liver cells (Giri et al., 1995) which may indicate additional nonimmune functions as compared to IL-2 which is only expressed on immune cells (Tagaya et al., 1996) .
Like IL-2, IL-15 induces T-cell proliferation and interferongamma (IFN-γ) production. In addition, IL-15 induces cytokine production by monocytes and polymorphonuclear cells (Carson et al., 1995) . The main difference between IL-2 and IL-15 occurs in vivo. Whereas IL-2 signaling results in termination of lymphocyte responses, IL-15 is an anti-apoptotic cytokine (Bulfone-Paus et al., 1997) . Despite the widespread expression of IL-15 intracellulary as measured both at the protein and mRNA level, there are only low levels of IL-15 secretion both in vivo and in vitro. It has also been reported that under physiological conditions human monocytes constitutively express membranebound, biologically active, and IFN-γ inducible IL-15 (Musso et al., 1999) .
IL-15 has been found to play a role in the pathogenesis of a variety of immune mediated diseases including rheumatoid arthritis, allograft rejection, sarcoidosis, and inflammatory bowel disease (Liu et al., 2000) . IL-15 has chemoattractant properties in the synovial fluid of patients with active RA (Li et al., 1998; McInnes et al., 1996) and in collagen-induced arthritis in animals, administration of soluble IL-15Rα prevented the disease (Ruchatz et al., 1998) .
MS is an inflammatory demyelinating disease of the central nervous system felt to be T cell mediated autoimmune disease (Weiner, 2004) . Pro-inflammatory cytokines such as IFN-γ, IL-12, IL-23 and IL-17 are believed to have an important role in the pathogenesis of MS. Although IL-15 appears to have an important role in the pathogenesis of a variety of inflammatory/autoimmune conditions, there are few studies on the production of IL-15 and its effect in patients with MS. It has been reported that MS patients
